BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 11406551)

  • 21. Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity.
    Dutoit V; Rubio-Godoy V; Dietrich PY; Quiqueres AL; Schnuriger V; Rimoldi D; Liénard D; Speiser D; Guillaume P; Batard P; Cerottini JC; Romero P; Valmori D
    Cancer Res; 2001 Aug; 61(15):5850-6. PubMed ID: 11479225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of antitumor cytotoxic T lymphocytes from the peripheral blood mononuclear cells of cancer patients using HLA-A2-restricted MAGE-3 peptide in vitro.
    Fujie T; Tanaka F; Mori M; Takesako K; Sugimachi K; Akiyoshi T
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2425-30. PubMed ID: 9815643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin.
    Piesche M; Hildebrandt Y; Zettl F; Chapuy B; Schmitz M; Wulf G; Trümper L; Schroers R
    Hum Immunol; 2007 Jul; 68(7):572-6. PubMed ID: 17584578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes.
    Lu J; Celis E
    Cancer Res; 2000 Sep; 60(18):5223-7. PubMed ID: 11016651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lysis of human chondrosarcoma cells by cytolytic T lymphocytes recognizing a MAGE-A3 antigen presented by HLA-A1 molecules.
    Bluman EM; Coulie PG; Xiaojuan S; Machan J; Lin C; Meitner PA; Block JA; Terek RM
    J Orthop Res; 2007 May; 25(5):678-84. PubMed ID: 17290408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Immunotherapeutic efficacy of both helper T lymphocytes and cytotoxic T lymphocytes epitopes augmented dendritic cells tumor vaccine on gastric cancer].
    Li Q; Zhang Y; Chen XH; Cao WX; Gu QL; Zhu ZG; Liu BY
    Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Mar; 9(2):148-51. PubMed ID: 16555158
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel strategy for the discovery of MHC class II-restricted tumor antigens: identification of a melanotransferrin helper T-cell epitope.
    Röhn TA; Reitz A; Paschen A; Nguyen XD; Schadendorf D; Vogt AB; Kropshofer H
    Cancer Res; 2005 Nov; 65(21):10068-78. PubMed ID: 16267033
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope.
    Sotiriadou R; Perez SA; Gritzapis AD; Sotiropoulou PA; Echner H; Heinzel S; Mamalaki A; Pawelec G; Voelter W; Baxevanis CN; Papamichail M
    Br J Cancer; 2001 Nov; 85(10):1527-34. PubMed ID: 11720440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens.
    Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S
    Immunol Lett; 2005 Jun; 99(1):85-93. PubMed ID: 15894116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides.
    Zhang XM; Zhang YF; Huang Y; Qu P; Ma B; Si SY; Li ZS; Li WX; Li X; Ge W; Hu PZ; Sui YF
    Oncol Rep; 2008 Jul; 20(1):245-52. PubMed ID: 18575744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prediction synthesis and identification of HLA-A2-restricted cytotoxic T lymphocyte epitopes of the tumor antigen MAGE-n].
    Dong HL; Sui YF; Ye J; Li ZS; Qu P; Zhang XM; Chen GS; Lu SY
    Zhonghua Yi Xue Za Zhi; 2003 Jun; 83(12):1080-3. PubMed ID: 12899783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide.
    van Bergen J; Camps M; Offringa R; Melief CJ; Ossendorp F; Koning F
    Cancer Res; 2000 Nov; 60(22):6427-33. PubMed ID: 11103809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601.
    van der Bruggen P; Szikora JP; Boël P; Wildmann C; Somville M; Sensi M; Boon T
    Eur J Immunol; 1994 Sep; 24(9):2134-40. PubMed ID: 7522162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
    Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.
    Zhang Y; Renkvist N; Sun Z; Schuler-Thurner B; Glaichenhaus N; Schuler G; Boon T; van der Bruggen P; Colau D
    Eur J Immunol; 2005 Apr; 35(4):1066-75. PubMed ID: 15756643
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A newly identified MAGE-3-derived, HLA-A24-restricted peptide is naturally processed and presented as a CTL epitope on MAGE-3-expressing gastrointestinal cancer cells.
    Miyagawa N; Kono K; Mimura K; Omata H; Sugai H; Fujii H
    Oncology; 2006; 70(1):54-62. PubMed ID: 16446550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of promiscuous HLA-DR-restricted CD4⁺ T-cell epitopes on the cancer-testis antigen HCA587.
    Wen W; Zhang L; Peng J; Chen J; Hao J; Li X; Qian X; Zeng P; Zhang Y; Yin Y
    Cancer Sci; 2011 Aug; 102(8):1455-61. PubMed ID: 21595801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
    Ayyoub M; Rimoldi D; Guillaume P; Romero P; Cerottini JC; Valmori D; Speiser D
    Cancer Res; 2003 Sep; 63(17):5601-6. PubMed ID: 14500401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine.
    Hu X; Chakraborty NG; Sporn JR; Kurtzman SH; Ergin MT; Mukherji B
    Cancer Res; 1996 Jun; 56(11):2479-83. PubMed ID: 8653680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry.
    Pascolo S; Schirle M; Gückel B; Dumrese T; Stumm S; Kayser S; Moris A; Wallwiener D; Rammensee HG; Stevanovic S
    Cancer Res; 2001 May; 61(10):4072-7. PubMed ID: 11358828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.